|
|
Volumn 34, Issue 8-9, 2011, Pages 469-470
|
|
Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: A bicentric phase II study
a
|
|
Author keywords
Cholangiocarcinoma Biliary tract cancer; Imatinib mesylate; Tyrosine kinase inhibitor
|
|
Indexed keywords
2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE;
FLUORODEOXYGLUCOSE F 18;
IMATINIB;
ADULT;
ADVANCED CANCER;
AGED;
ALKALINE PHOSPHATASE BLOOD LEVEL;
AMINOTRANSFERASE BLOOD LEVEL;
ANEMIA;
AREA UNDER THE CURVE;
BILIARY TRACT CANCER;
BILIRUBIN BLOOD LEVEL;
CANCER DIAGNOSIS;
CANCER GROWTH;
CANCER PALLIATIVE THERAPY;
CANCER STAGING;
CANCER SURVIVAL;
CLINICAL ARTICLE;
COMPUTER ASSISTED TOMOGRAPHY;
CONTROLLED STUDY;
DRUG DOSE ESCALATION;
DRUG DOSE REDUCTION;
DRUG TOLERABILITY;
FEMALE;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
HUMAN;
IMMUNOHISTOCHEMISTRY;
LETTER;
MALE;
MAXIMUM PLASMA CONCENTRATION;
MORNING DOSAGE;
NUCLEAR MAGNETIC RESONANCE IMAGING;
OVERALL SURVIVAL;
POSITRON EMISSION TOMOGRAPHY;
PROGRESSION FREE SURVIVAL;
SIDE EFFECT;
TIME TO MAXIMUM PLASMA CONCENTRATION;
VOMITING;
AGED;
ANTINEOPLASTIC AGENTS;
BILE DUCT NEOPLASMS;
CHOLANGIOCARCINOMA;
DISEASE-FREE SURVIVAL;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FEMALE;
GALLBLADDER NEOPLASMS;
HUMANS;
MALE;
MIDDLE AGED;
NEOPLASM STAGING;
PALLIATIVE CARE;
PIPERAZINES;
PROSPECTIVE STUDIES;
PYRIMIDINES;
|
|
EID: 80053285626
PISSN: 0378584X
EISSN: 14230240
Source Type: Journal
DOI: 10.1159/000331065 Document Type: Letter |
|
Times cited : (24)
|
|
References (4)
|
